Hyasynth Bio

🗓 Founded 2014👥 21 employees💰 Last funded Aug 2017
Biotechnology Research🌐 hyasynthbio.com
Website LinkedIn
Biology for people. Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes. We use the technologies from traditional and modern biology combined with computational analysis to develop our organisms at the fastest possible speed. This makes our platform faster and cheaper than chemical synthesis or extraction from the natural source.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in Hyasynth Bio?
Hyasynth Bio has 1 investors on record on gritt.io, 1 mid-stage.
When did Hyasynth Bio last raise funding?
The most recent investment in Hyasynth Bio recorded on gritt.io was in August 2017.
When was Hyasynth Bio founded?
Hyasynth Bio was founded in 2014.
What industry is Hyasynth Bio in?
Hyasynth Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.